Dharmacon and Amaxa Collaborate to Improve siRNA Delivery into Cells
News Jun 07, 2006
Dharmacon, Inc., a business unit of the Fisher Biosciences group and amaxa have announced an agreement to co-promote data generated using Dharmacon's siRNA libraries with amaxa's Nucleofector® technology.
Despite the rapid advance of RNAi gene silencing for drug discovery and development, some research has been hampered by the insufficient delivery of siRNA into primary cells and non-standard cell lines.
Nucleofection gives researchers the ability to efficiently transfer nucleic acids into those cells and use them for gene silencing experiments.
Amaxa's Nucleofector® 96-well Shuttle™ system are designed to allow parallel processing of a large number of transfection experiments and works well with Dharmacon's libraries as well as smaller siRNA samples.
"The combined technologies of Dharmacon and amaxa enable us to broaden the application of siRNA so that it can be introduced into difficult cell lines, and with the 96-well Shuttle system researchers can also accomplish this in high throughput," said William S. Marshall, Ph.D., vice president of technology and business development for Fisher Biosciences.
"We will work closely with amaxa to provide our customers with coordinated technical service, pre-tested protocols and application models to optimize the use of our siRNA reagents with the amaxa technology."
Rainer Christine, CEO of amaxa, said, "We believe Dharmacon provides excellent-quality siRNA, and that made the company an obvious choice for partnering."
"At amaxa, we provide our customers with solutions for whichever cell types they consider the best model system for their experiments. By working closely with Dharmacon, we can help researchers accelerate the speed and accuracy of their experiments using siRNA."
In treating inflammatory bowel disease (IBD), physicians can have a hard time telling which newly diagnosed patients have a high risk of severe inflammation or what therapies will be most effective. Now researchers report finding an epigenetic signature in patient cells that appears to predict inflammation risk in a serious type of IBD called Crohn’s disease.